Fusconi Marco, Vannini Antonio, Dall'Aglio Anna Chiara, Pappas Georgios, Bianchi Francesco B, Zauli Daniela
Internal Medicine Department, Azienda Ospedaliero-Universitaria di Bologna, Policlinico S.Orsola-Malpighi, Bologna, Italy.
Rheumatol Int. 2007 Nov;28(1):47-9. doi: 10.1007/s00296-007-0379-5. Epub 2007 Jun 13.
Etanercept and infliximab treatments are often associated with autoantibodies induction. Their reported prevalences vary among different studies and the conclusions are somehow conflicting, mainly regarding whether the two drugs induce the same modifications. In this small prospective study, specifically designed to identify transient phenomena, we assess the prevalence of different relevant rheumatologic autoantibodies during anti-TNF-alpha courses in patients with rheumatoid arthritis. We report that both etanercept and infliximab transiently induce anti-DNA antibodies in 50-78% of patients, respectively, and these antibodies seem to be different from the typical lupus associated ones. Antinuclear antibodies (ANA) increased their titres and were newly produced up to 100% of patients. No other relevant antibodies are affected. Finally, as also confirmed for the first time by the patients switched from one drug to the other, the two TNF-alpha blockers behave similarly.
依那西普和英夫利昔单抗治疗常与自身抗体的诱导有关。不同研究报道的其发生率有所不同，结论也存在一定冲突，主要涉及这两种药物是否诱导相同的改变。在这项专门设计用于识别短暂现象的小型前瞻性研究中，我们评估了类风湿关节炎患者在抗TNF-α治疗过程中不同相关风湿性自身抗体的发生率。我们报告称，依那西普和英夫利昔单抗分别在50%-78%的患者中短暂诱导抗DNA抗体，且这些抗体似乎与典型的狼疮相关抗体不同。抗核抗体（ANA）滴度升高，在高达100%的患者中出现新产生的情况。没有其他相关抗体受到影响。最后，正如首次在从一种药物转换为另一种药物的患者中所证实的那样，两种TNF-α阻滞剂的表现相似。
